News
EBS
5.85
-0.85%
-0.05
Emergent BioSolutions Gets Anthrax Vaccine Contract Modification Up to $22.3M
Dow Jones · 1d ago
Emergent BioSolutions receives $22.3M delivery order modification
TipRanks · 1d ago
Emergent BioSolutions Secures $22.3 Million Anthrax Vaccine Contract Modification
TipRanks · 1d ago
Emergent BioSolutions Awarded $22.3M Contract Modification To Provide BioThrax To U.S. Department Of War
Benzinga · 1d ago
Emergent BioSolutions trading resumes
TipRanks · 2d ago
Emergent BioSolutions trading halted, volatility trading pause
TipRanks · 2d ago
Adeia Posts Downbeat Q3 Earnings, Joins Bioventus, Apple And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Benzinga · 3d ago
Emergent Shares Slide as 3Q Revenue Shrinks
Dow Jones · 3d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 3d ago
Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors
NASDAQ · 3d ago
Why Aehr Test Systems Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Benzinga · 3d ago
Emergent BioSolutions Q3 2026 Earnings Call Transcript
Benzinga · 3d ago
Emergent BioSolutions Reports Third-Quarter 2026 Results and Restructuring
TipRanks · 3d ago
Emergent BioSolutions reports Q3 adjusted EPS (36c), two estimates (39c)
TipRanks · 3d ago
Emergent BioSolutions cuts FY26 revenue view to $600M-$645M, consensus $657.12M
TipRanks · 3d ago
*Emergent Biosolutions 3Q Adj Loss/Shr 36c >EBS
Dow Jones · 3d ago
*Emergent Biosolutions 3Q Loss/Shr 64c >EBS
Dow Jones · 3d ago
Press Release: Emergent Biosolutions Reports -3-
Dow Jones · 3d ago
Here are the major earnings after the close Monday
Seeking Alpha · 3d ago
Weekly Report: what happened at EBS last week (1026-1030)?
Weekly Report · 4d ago
More
Webull provides a variety of real-time EBS stock news. You can receive the latest news about Emergent Biosolutions Inc through multiple platforms. This information may help you make smarter investment decisions.
About EBS
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.